Clinical Trial Update: A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ganetespib (STA-9090) in patients with metastatic and/or unresectable gastrointestinal stromal tumor has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• STA-9090 (ganetespib)

Snippet

Sponsor: Synta Pharmaceuticals Corp. | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: COMPLETED | Results posted: 2016-03-10